Market Research Logo

Prostate Cancer: Update Bulletin #2 [April 2018]

Prostate Cancer: Update Bulletin #2 [April 2018]

Introduction

Gain new key opinion leader (KOL) insights on the latest events happening in the prostate cancer space. Topics covered include expert opinions on the FDA approval of Johnson & Johnson’s (J&J’s) next-generation androgen receptor inhibitor Erleada (apalutamide) in patients with non-metastatic castration-resistant prostate cancer (CRPC), data published from the PROSPER study for Pfizer/Astellas’ Xtandi (enzalutamide) in the non-metastatic CRPC population and the expanded approval for J&J’s Zytiga (abiraterone acetate) by the FDA in patients with high-risk metastatic hormone-sensitive prostate cancer (mHSPC). Finally, the experts also provide candid insights into their expectations for Pfizer’s PARP inhibitor talazoparib which has entered Phase III development (TALAPRO-2 study) in combination with physician's choice of either Xtandi or Zytiga in patients with metastatic CRPC.

Business Questions

What are the experts’ opinions on the FDA approval of J&J’s Erleada in patients with non-metastatic CRPC based on the novel endpoint of metastasis-free survival (MFS)?

How do KOLs contrast and compare the efficacy of Erleada and Pfizer/Astellas’ Xtandi in the non-metastatic CRPC setting?

In terms of safety, how do KOLs view the data reported for Erleada in the SPARTAN study?

Do the KOLs anticipate Erleada and Xtandi to compete head-to-head for market share in the non-metastatic CRPC setting? If so, what will influence their prescribing choices?

How do the experts view the expanded approval for J&J’s Zytiga in patients with mHSPC? Will the drug gain significant uptake in this setting going forward?

Will Xtandi be able to compete with Zytiga in the mHSPC setting? What data do KOLs expect from the recently completed ENZAMET/ARCHES studies investigating Xtandi?

What are KOL expectations for Pfizer’s PARP inhibitor talazoparib in prostate cancer and how can it differentiate itself from the other two PARP inhibitors in Phase III development [AstraZeneca’s Lynparza (olaparib) and Clovis Oncology’s Rubraca (rucaparib)]?

In terms of mechanism of action, efficacy and safety, how do the three PARP inhibitors compare so far?

Do KOLs think Pfizer’s combination of talazoparib with anti-androgen drugs in the TALAPRO-2 study is a promising strategy?

If approved in prostate cancer, how and when will the PARP inhibitors be used?


Please Note: Due to the brevity and/or nature of the content posted, there is no table of contents available for this report.

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report